Navigation Links
Intrexon Announces Third Quarter Financial Results
Date:11/7/2013

ecognized during the period and includes the cash and stock received from collaborators for upfront and milestone payments during the period. We believe that adjusting for the impact of the change in deferred revenue in this manner is important since it permits us to make quarterly and annual comparisons of our ability to consummate new collaborations or to achieve significant milestones with existing collaborators. Further, we believe it is useful when evaluating our financial and operating performance, generating future operating plans and making strategic decisions about the allocation of capital.

Pro forma adjusted EBITDA per share.  Our calculations for pro forma adjusted EBITDA per share, basic and diluted, assumes, as of the end of the respective period, the conversion of all outstanding shares of our redeemable convertible preferred stock plus all cumulative dividends payable thereon into shares of common stock as if such conversion had occurred as of the later of (i) the beginning of the period or (ii) the issuance date of those shares.  Because all of our shares of redeemable convertible preferred stock and all accrued and cumulative dividends thereon automatically converted into common shares upon the closing of our initial public offering on August 13, 2013, we believe that the inclusion of such shares on an as-converted basis results in a useful metric for our investors, analysts and others when evaluating our results on a comparable basis with other periods.  While our management and board of directors believe that this non-GAAP per share metric is useful in evaluating our past adjusted EBITDA results, and may be of use to investors, analysts and others, this information should be considered supplemental in nature and is not meant as a substitute for the per share information prepared in accordance with GAAP.  In addition, this non-GAAP per share metric may not be the same as non-GAAP per share metrics presented by ot
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
2. Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results
3. Pro-Dex, Inc. Announces Fiscal 2014 First Quarter Financial Results Conference Call And Webcast
4. DURECT Announces Proposed Public Offering of Common Stock
5. Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
6. Star Scientific Announces Leadership Transition, Acceleration of Plans for Submission of an IND to FDA for Pharmaceutical Version of Anatabine Compound
7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
8. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
9. PDL BioPharma Announces Third Quarter 2013 Financial Results
10. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
11. Heska Announces Financial Results for the Third Quarter of Fiscal 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... , , MONMOUTH JUNCTION, ... from a Phase II clinical trial in non-cystic fibrosis (CF) ... (liposomal amikacin for inhalation). The Phase II data indicated that ... clinical benefit compared to placebo as measured by patient and ...
... , TARRYTOWN, N.Y., Sept. 14 ... announced the completion of patient enrollment in two randomized, double-masked, ... of the neovascular form of age-related macular degeneration (wet AMD). ... of Efficacy and Safety in Wet AMD) program, VEGF Trap-Eye ...
Cached Medicine Technology:Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 2Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 3Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 2Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 3Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 5
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/26/2014)... Parker & Sons, Inc. a ... heating, cooling and plumbing contractor services throughout Arizona ... in 2014 with regard to air-conditioning systems. Residential ... known for its incredibly hot summers. Working with ... and details of a wide variety of systems ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3
... Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and ... PDLI ) and Alexion Pharmaceuticals, Inc. (Nasdaq: ... have entered into a definitive license agreement and settlement agreement ... humanized antibody, Soliris(R) (eculizumab) and PDL,s patents known as the ...
... Jan. 5 The Ensign Group, Inc. (Nasdaq: ... has acquired Southland Healthcare Center, a 150-bed skilled ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"This is a strategic acquisition, and ...
... The Ensign Group, Inc. (Nasdaq: ... Cabrillo Care Center, a 156-bed skilled nursing facility ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"We are excited to extend our ...
... Campaign of Upscale Properties in Denver, Colorado , ... ... estate auction marketing firm, LFC Group of Companies, launched a new ... residential real estate website, Freedom Realty Exchange ( FRE.com/284R3 ). The ...
... Help us, help the Red Cross meet the winter demand for blood. January ... Wilmington MA. We,ll give you FREE oil change if you,re one of the first ... ... the American Red Cross are asking people to come out and give blood as ...
... informatics platform, OnCore®, achieved another milestone this ... multidisciplinary research organization. At the end of ... Clinical and Translational Research (UWICTR) began using ... collection and administration needs. OnCore is the ...
Cached Medicine News:Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3Health News:The Ensign Group Acquires Texas Skilled Nursing Facility 2Health News:The Ensign Group Acquires California Skilled Nursing Facility 2Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 2Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 3Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 4Health News:Boston Hyundai Dealer Teams up With the Red Cross to Save Lives 2Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 2Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 3Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 4
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... Increase Staff Protection With Medline's Sterile Suction Catheters ... 16 Fr and 18 Fr), ,Medline is ... U.S. We manufacture most of our suction products ... our customers' expectations. We manufacture, supply and directly ...
... Catheters are available in ... atraumatic DeLee tip with staggered ... tip. Two types of catheter ... deliver easy fingertip control with ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
Medicine Products: